Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1000 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated or use in haemophilia a for prevention and control of haermorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von wllebrand's disease

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 250 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of harmorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5 mg/ml - diluent, not applicable - excipient ingredients: metacresol; water for injections - short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 20 march 2001: short stature due to decreased or failed secretion of pituitary hormone. growth distrubances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 26 november 2001: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanograms/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituit

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 2000 iu - diluent, not applicable - excipient ingredients: sodium chloride; water for injections - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 483 mg (equivalent: olanzapine, qty 210 mg) - diluent, not applicable - excipient ingredients: carmellose sodium; mannitol; hydrochloric acid; polysorbate 80; sodium hydroxide; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 690 mg (equivalent: olanzapine, qty 300 mg) - diluent, not applicable - excipient ingredients: hydrochloric acid; polysorbate 80; carmellose sodium; mannitol; sodium hydroxide; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 931 mg (equivalent: olanzapine, qty 405 mg) - diluent, not applicable - excipient ingredients: hydrochloric acid; carmellose sodium; sodium hydroxide; mannitol; polysorbate 80; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 1995 pfu; rubella virus, quantity: 1000 ccid50; measles virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.